AVA Bio Defender
Mutation-resistant Viral Defense Technologies
Company Overview
Snapshot
Founded in January 2007 by Lior Zigler, AVA Bio Defender operates with 1–10 employees. The company has raised $2.5 million across one funding round, focusing on developing mutation-resistant viral defense technologies.
Business overview
AVA Bio Defender is a biotechnology company specializing in the development of mutation-resistant viral defense technologies. The company utilizes siRNA and CRISPR technologies to create heritable genetic resistance in animals, particularly for poultry, and designs drug therapies for human use. Its core product involves a gene-delivery system for antiviral protection in animal cells and molecules for human therapy that are effective against viral mutations. AVA Bio Defender serves the animal health and pharmaceutical markets globally, operating within the Health Tech & Life Sciences sector, specifically in Pharma & Medical Biotechnology, Drugs Discovery & Development, and Drug Delivery.
Company Intelligence Q&A
- What is AVA Bio Defender's primary focus?
- AVA Bio Defender specializes in developing mutation-resistant viral defense technologies, including heritable genetic resistance in animals and drug design for human therapy.
- What technologies does AVA Bio Defender utilize?
- The company uses siRNA technology for a gene-delivery system to provide antiviral protection in animal cells and CRISPR technology for directed editing of target genomes in animals. For human therapy, it develops molecules effective against viral mutations.
- Which markets does AVA Bio Defender target?
- AVA Bio Defender targets the global animal health market, specifically poultry, and the pharmaceutical market for human therapies.
- Who founded AVA Bio Defender?
- AVA Bio Defender was founded by Lior Zigler in January 2007.
- What is the current product stage for AVA Bio Defender?
- AVA Bio Defender's products are currently in the Clinical Trial stage, focusing on developing a gene-delivery system for antiviral protection in animal cells and molecules for human therapy.